Everolimus: adverse event reports filed with FDA

13,640

reports as suspect product

0.1% of all reports · about 609 a year

1,188

reports, 12 months to June 2026

1,191 in the 12 months before

89.5%

marked serious by the reporter

70.8% across the class

16.1%

record death among outcomes, as reported

2,197 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Everolimus reports recording the termmedian drug in kinase inhibitor

1. Malignant neoplasm progression10%1,369
2. Off label useused for a purpose or in a way not on the label6.9%945
3. Diarrhoealoose or frequent stools6.8%924
4. Drug ineffectivethe medicine did not work as expected5.9%805
5. Fatiguetiredness4.9%669
6. Disease progressionthe disease advanced4.9%662
7. Product use in unapproved indicationused for a purpose not on the label4.8%652
8. Deaththe patient died; cause not stated by this term4.8%649
9. Nauseafeeling sick4.3%586
10. Dyspnoeashortness of breath4.2%568
11. Pneumonialung infection3.9%532
12. Pyrexiafever3.8%514
13. Vomitingbeing sick3.5%471
14. Drug interactionan interaction between medicines3.4%457
15. Anaemialow red blood cells3.3%455
16. Metastases to liver3.2%443
17. Pneumonitis3.1%419
18. Stomatitissore mouth3.1%419
19. Metastases to bone2.8%386
20. Acute kidney injurysudden loss of kidney function2.8%385
21. Decreased appetitereduced appetite2.7%366
22. Thrombocytopenialow platelets2.7%363
23. Neutropenialow neutrophils, a type of white blood cell2.5%345
24. Astheniaweakness or lack of energy2.5%339
25. Renal impairmentreduced kidney function2.4%329
26. Pleural effusionfluid around the lung2.3%315
27. Coughcough2.3%312
28. Weight decreasedweight loss2.2%306
29. Toxicity to various agentspoisoning or toxic effect of one or more substances2.2%296
30. Rashskin rash2.2%294

Top 30 of 1,902 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 100 drugs in the kinase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 849,161 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 33.8% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 13,640 reports.

Drugs most often listed in the same reports

Other products listed in reports where Everolimus is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the kinase inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Everolimus as a suspect or interacting product; reports listing it only as a concomitant medication (3,235) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.